Source podcast
Peter Diamandis and his Moonshot Mates, among them Salim Ismail, Dave Blundin and Alexander Wissner-Gross, on technology, science and ambitious ideas about the future.
Discussing Elon Musk's sunlight-adjusting satellite idea, Peter Diamandis said blocking sunlight is simple but deciding who controls it is broken; Alexander Wissner-Gross proposed a global weather market, which a co-host called naive.
Sam Altman told TIME he expects an internal OpenAI system he would call AGI by year-end. Moonshots panelists speculated the leap may be agents that keep their memory over very long tasks instead of losing context.
OpenAI has proposed ending Cursor's access to its models on 12 November, after SpaceX bought Cursor. On Moonshots, one panelist saw a bet on OpenAI's own enterprise stack; another argued the real prize is reasoning traces.
Architect Labs says its AI designed the Redwood accelerator from a two-architect spec, reaching verified FPGA deployment in two weeks; its 3.4× efficiency edge over Nvidia's Jetson is a projection for an unbuilt chip.
PSI's AI found in a week a cheap Alpha Centauri route that eluded StarCloud's Philip Johnston for six months: slow down, fall toward the sun, thrust at perihelion. The sub-$15M probe would take roughly 77,500 years and miss by about 2,600 AU.
Tim Sweeney tweeted that Elon Musk's predicted 100x gain in intelligence per gigabyte has come true; Musk says specialist AIs add another 100x. Dave asks how 10,000 agents would work together; Alex says specialists are really sparsification.
Peter Diamandis said a Unitree humanoid built in three months ran 12.66 m/s, above Bolt's 12.4. Salim Ismail urged non-human designs, Alexander Wissner-Gross bet on general-purpose bodies, and Emad Mostaque predicted street limits on extreme robots.
Peter Diamandis, after meeting SK hynix and Solidigm leaders, argued memory, not GPUs, now limits AI. Panelists blamed new AI workloads and bust-wary suppliers, and floated etching model weights into chips as a possible fix.
GenBio's AIDO Cell simulates a human cell that remembers successive edits and drugs. For now it helps prioritize experiments in two cell lines; lab validation of its novel predictions is underway. A Moonshots panelist called it the end of medicine.
Merck and Moderna said personalized mRNA therapy intismeran autogene plus Keytruda beat Keytruda alone on melanoma recurrence-free and distant-metastasis-free survival in a 1,137-patient phase 3 interim analysis. No effect sizes were released.
Uber is investing in Zipline and adding its drones to Uber Eats, targeting one million deliveries a day by end-2029. Moonshots panelists saw it as a test of Uber aggregating demand while suppliers, who could sell direct, own the robots.
Dave Blundin of Link Ventures says one bad coding idea can spread through all 5,000 of his identical AI agents, costing roughly $50,000 in tokens unless he rewinds them. Panelists linked it to a paper on "mind viruses" spreading between agents.
.avif)
